Abstract
Glucose and cell swelling induce insulin secretion by alternative signaling pathways. Swelling-induced secretion is in most systems independent of calcium and various mediators of glucose stimulation. Comparison of two insulinoma tumor cell lines revealed surprising difference; INS-1E cells in contrast to INS-1 cells and isolated rat pancreatic islets do not respond to hypotonicity in the presence of calcium. To delineate the role of cholesterol the effect of its extraction or addition on the insulin secretion in response to glucose and cell swelling was compared. INS-1E cells have significantly higher cholesterol content than INS-1 cells (58.5 ± 2.9 and 46.3 ± 2.5 mg chol/mg prot respectively). After cholesterol desorption by 1.0, 5.0 and 10.0 mM of carboxymethyl-β-cyclodextrin, methyl-β-cyclodextrin, or 2-hydroxypropyl-β- cyclodextrin the response to hypotonicity in INS-1E cells emerged. On the contrary, supplementation of INS-1 cells with cholesterol inhibited their response to cell swelling. Cyclodextrin pretreatment inhibited glucose-induced insulin secretion from INS-1 cells while INS-1E cells were more resistant to their effect. Conclusion: Cellular cholesterol content substantially affects secretory process; both high and low levels could be inhibitory. Absence of swelling-induced insulin secretion in INS-1E cells despite adequate response to glucose is related to their high cholesterol content. Optimal cholesterol concentration is different for either type of stimulation; swelling-induced mechanism is more sensitive to higher cholesterol content. The difference is likely to reflect involvement of sequential type exocytosis after cell swelling. Sensitivity of secretory processes suggests that either hypercholesterolemia or excessive effort to decrease plasma cholesterol in patients could have adverse effect on insulin secretion.
Keywords: Cell volume, cholesterol, insulin secretion, sequential exocytosis, glucose, cyclodextrins, insulin, calcium, ion-flux modifiers
Medicinal Chemistry
Title: Effect of Cellular Cholesterol Changes on Insulin Secretion by Tumor Cell Lines
Volume: 8 Issue: 1
Author(s): Bacova Z., Hafko R., Orecna M., Kohut P., Hapala I. and Strbak V.
Affiliation:
Keywords: Cell volume, cholesterol, insulin secretion, sequential exocytosis, glucose, cyclodextrins, insulin, calcium, ion-flux modifiers
Abstract: Glucose and cell swelling induce insulin secretion by alternative signaling pathways. Swelling-induced secretion is in most systems independent of calcium and various mediators of glucose stimulation. Comparison of two insulinoma tumor cell lines revealed surprising difference; INS-1E cells in contrast to INS-1 cells and isolated rat pancreatic islets do not respond to hypotonicity in the presence of calcium. To delineate the role of cholesterol the effect of its extraction or addition on the insulin secretion in response to glucose and cell swelling was compared. INS-1E cells have significantly higher cholesterol content than INS-1 cells (58.5 ± 2.9 and 46.3 ± 2.5 mg chol/mg prot respectively). After cholesterol desorption by 1.0, 5.0 and 10.0 mM of carboxymethyl-β-cyclodextrin, methyl-β-cyclodextrin, or 2-hydroxypropyl-β- cyclodextrin the response to hypotonicity in INS-1E cells emerged. On the contrary, supplementation of INS-1 cells with cholesterol inhibited their response to cell swelling. Cyclodextrin pretreatment inhibited glucose-induced insulin secretion from INS-1 cells while INS-1E cells were more resistant to their effect. Conclusion: Cellular cholesterol content substantially affects secretory process; both high and low levels could be inhibitory. Absence of swelling-induced insulin secretion in INS-1E cells despite adequate response to glucose is related to their high cholesterol content. Optimal cholesterol concentration is different for either type of stimulation; swelling-induced mechanism is more sensitive to higher cholesterol content. The difference is likely to reflect involvement of sequential type exocytosis after cell swelling. Sensitivity of secretory processes suggests that either hypercholesterolemia or excessive effort to decrease plasma cholesterol in patients could have adverse effect on insulin secretion.
Export Options
About this article
Cite this article as:
Z. Bacova, R. Hafko, M. Orecna, P. Kohut, I. Hapala and V. Strbak, Effect of Cellular Cholesterol Changes on Insulin Secretion by Tumor Cell Lines, Medicinal Chemistry 2012; 8 (1) . https://dx.doi.org/10.2174/157340612799278504
DOI https://dx.doi.org/10.2174/157340612799278504 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Strategies for Hepatitis B virus-Associated Hepatocellular Carcinoma
Current Drug Targets Drug Delivery Systems for Diabetes Treatment
Current Pharmaceutical Design Mild Cognitive Impairment: At the Crossroad of Neurodegeneration and Vascular Dysfunction
Current Alzheimer Research Coagulation and Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Neuro-Psychiatric Alterations in Patients with Diabetic Foot Syndrome
CNS & Neurological Disorders - Drug Targets GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Preparation, Characterization and In Vivo Assessment of Repaglinide Nanosuspension for Oral Bioavailability Improvement
Recent Patents on Drug Delivery & Formulation Metabolic Syndrome and Non-Cardiac Vascular Diseases: An Update from Human Studies
Current Pharmaceutical Design Lead Optimization Resources in Drug Discovery for Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Vitamin D3, D2 and Arterial Wall Properties in Coronary Artery Disease
Current Pharmaceutical Design Cardiovascular Pharmacogenetics of Antihypertensive and Lipid- Lowering Therapies
Current Molecular Medicine Recent Advances in Polymer-based Wound Dressings for the Treatment of Diabetic Foot Ulcer: An Overview of State-of-the-art
Current Drug Targets Copper and Neurotoxicity in Autism Spectrum Disorder
Current Pharmaceutical Design The GABA A Receptor Subunits Heterologously Expressed in Xenopus Oocytes
Mini-Reviews in Medicinal Chemistry Current Progress of Lipid Analysis in Metabolic Diseases by Mass Spectrometry Methods
Current Medicinal Chemistry Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Current Drug Therapy The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology The Role of the Brain Renin-Angiotensin System in Neurodegenerative Disorders
Current Alzheimer Research Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research